In order to examine the effect of hematopoietic stem cell transplantation (HSCT) on cardiac systolic function, we measured left ventricular ejection fraction (LVEF) by radioventriculography (RVG) before and after the transplantation procedure. One hundred and fortyeight patients were examined, 96 undergoing allogeneic grafting and 52 autologous. Fifty patients had CML, 48 AML, 21 ALL, 18 multiple myeloma and 11 breast cancer. The second RVG examination was performed 22 to 227 days (median 60 days) after HSCT. The mean LVEF value in the whole patient group was 60.2% (range 39-81%) before and 61.1% (35-86%) after transplantation. Patients with CML had significantly higher LVEF before transplantation than patients with acute leukemia (P = 0.007) and multiple myeloma (P = 0.005). No significant changes in mean LVEF between the pre-and post-transplant measurements were seen in any of the diagnostic subgroups or in allogeneic or autologous recipients. None of the 148 patients in the study has shown any signs of clinical heart failure at 2, 5 to 10 years follow-up. Patients who had received anthracyclines in the previous treatment had significantly lower LVEF before transplantation but showed no increased risk of decline in cardiac function. In conclusion, the HSCT procedure does not seem to affect myocardial function 1-7 months after transplantation. Bone Marrow Transplantation (2000) 26, 187-192. Keywords: hematopoietic stem cell transplantation; cardiotoxicity; radioventriculography; anthracyclines Allogeneic or autologous HSCT offers a possibility of cure or long-term remission in hematological malignancies. However, gastrointestinal, pulmonary, infectious and immunological complications are major problems and limiting factors for HSCT. Acute cardiac toxicity has previously been described with mortality ranging from 1.2% to 9% and morbidity from 5% to 43%.
changes and transient arrhythmias, but pericarditis, heart failure, pulmonary edema and cardiac death are also seen. 1, 2 Conditioning therapy for HSCT usually consists of highdose chemotherapy with or without total body irradiation (TBI). The cardiotoxic effects of cyclophosphamide (CY), the most frequently used drug, are well known and consist of acute, dose-dependent cardiac damage, morphologically characterized by necrosis, hemorrhage and later development of fibrosis. [4] [5] [6] [7] [8] [9] Radiation has well-known effects on the heart and may cause pericarditis and myocardial fibrosis. [10] [11] [12] [13] [14] Ischemic heart disease caused by the effects of radiation on the coronary arteries has also been described. 15 Infections due to immunosuppression and affecting the myocardium are less well defined but can be considered as potentially cardiotoxic factors. Buja et al 16 found a correlation with graft-versushost disease (GVHD) and myocardial interstitial changes at autopsy. These factors could be expected to affect cardiac function in patients surviving the transplantation procedure.
In order to evaluate the effect of HSCT on cardiac systolic function we performed radioventriculography (RVG), measuring left ventricular ejection fraction (LVEF), before and after transplantation in 148 patients undergoing allogeneic or autologous HSCT. The pre-and post-transplant values were compared in different disease groups and in allogeneic and autologous recipients. As cardiotoxicity is a well-known side-effect of treatment with anthracyclines 14, [17] [18] [19] [20] we also investigated whether the use of anthracyclines in the previous treatment was a risk factor for decline in heart function after HSCT.
Materials and methods

Patients
Patients with AML, ALL, CML, multiple myeloma and breast cancer receiving allogeneic or autologous HSCT between 1985 and 1994 underwent a RVG examination before transplantation. One hundred and fifty-three consecutive patients who survived the transplantation procedure were studied. Five of the patients were lost to follow-up before the second RVG examination. Of the remaining 148 patients who underwent both pre-and posttransplant examinations, 50 had CML, 48 AML, 21 ALL, 18 multiple myeloma and 11 had breast cancer, 96 had received an allogeneic graft and 52 an autologous. All patients with ALL received an allogeneic graft and all patients with breast cancer an autologous. Table 1 shows the number of allogeneic vs autologous transplants in patients in the other diagnostic groups. The mean age at the time of transplantation was 39.1 years for all patients, 35.5 years for allogeneic recipients and 45.9 years for autologous.
Conditioning regimens
Patients with CML, AML and ALL received cyclophosphamide 60 mg/kg/day i.v. on 2 consecutive days and either total body irradiation with 10 Gy in one fraction with lungshielding to 9 Gy (n = 95) or busulfan 4 mg/kg/day p.o. . 23 Melphalan and all drugs in the CMF and CTCb courses were administered intravenously.
Previous treatment with anthracyclines
Seventy-two of the patients had received treatment with anthracyclines before transplantation. Doxorubicin, daunorubicin, idarubicin, and epirubicin had been used as well as mitoxanthrone. The doses were multiplied with a specific factor for each drug in order to calculate cardiotoxic doses equipotent to doxorubicin which had a factor of 1. The converting factors were based on previous studies of the equipotency of anthracycline doses and the cardiotoxic potential of the drugs. [24] [25] [26] The factor was 0.75 for daunorubicin, 0.75 for epirubicin, 3 for idarubicin and 3 for mitoxantrone. The patients were divided into three groups according to the cumulative doses, group 1 had received Ͻ250 mg/m 2 (n = 34), group 2 250-500 mg/m 2 (n = 37) and group 3 Ͼ500 mg/m 2 (n = 5) of doses equipotent to doxorubicin. Five CML patients, 41 AML patients, 18 ALL patients, five myeloma patients and 10 of the patients with breast cancer had received anthracyclines in their previous treatment.
Radionuclide scans
The first RVG examinations were performed within 3 weeks of HSCT and the second examinations were performed 22 to 227 days after the transplantation procedure (median 60 days). The RVG was performed with gated equilibrium technique. Blood cells were targeted with 99mTc-pertechnetate, facilitated by pyrophosphate and injected intravenously. ECG-gated gamma camera scanning was performed in left anterio-cranial projection to image the left ventricle separated as far as possible from the right ventricle and the left atrium. The trigger device divided the cardiac cycle into 32 phases. By semi-automatic computer processing one systolic and one diastolic phase image was chosen. On these images regions of interest were drawn: left ventricle and background. The background was drawn just lateral to the free wall of the left ventricle. LVEF was calculated. At repeated examinations care was taken to reproduce the scanning projection and regions of interest as closely as possible. Manual drawing of regions was undertaken to meet these demands. All examinations were performed by one technician and all post-processing and interpretation was carried out by one investigator. Significant decrease in the LVEF was defined as a decrease of more than 10 percentage points or a decrease to less than 50% based on previous studies.
27,28
Clinical evaluation
In patients with a significant decrease in LVEF or with less than 50% LVEF before HSCT, signs of heart failure were sought retrospectively. The follow-up time was 2.5 to 10 years. All patients were examined by chest X-ray and clinical examination and in some patients additional RVG examinations were conducted. Radiological and clinical signs such as exertional dyspnea, rales and pretibial edema considered to be of cardiac origin were noted.
Statistics
For descriptive statistics of LVEF values we used the arithmetic mean value together with the range. Student's paired t-test was used to compare changes in LVEF before and after HSCT. Unpaired t-test was used to evaluate differences in mean LVEF between diagnoses, graft modalities and anthracycline groups before HSCT. All tests were twosided. Comparisons of the incidence of significant decrease in LVEF between groups were evaluated by Fisher's exact test.
Results
LVEF before and after transplantation
The average pre-and post-transplant values with ranges and P values are presented in Table 2 . CML patients had significantly higher LVEF before transplantation than patients with acute leukemia (P = 0.007) and multiple myeloma (P = 0.005) but not compared to patients with breast cancer (P = 0.45). No significant difference in the pretransplant values was seen between allogeneic and autologous recipients (P = 0.25). Eleven patients had less than 50% (range 39-47%) in LVEF before HSCT (2 CML, 5 AML, 3 ALL, 1 multiple myeloma). The differences between pre-and post-transplant values were not significant in any of the subgroups defined by diagnosis or graft type, nor in the whole patient group.
Patients with a significant decrease in LVEF
In 10 patients the LVEF decreased more than 10 percentage points and in two patients there was a decrease to less than 50%. One patient with ALL decreased from 53% to 41% and fulfilled both criteria for significant decrease. Of the 11 patients with significant decrease, seven had acute leukemia, one CML, one multiple myeloma and two breast cancer. Eight out of 95 patients receiving allogeneic grafts had a significant decrease and two out of 47 receiving autologous (P = 0.75) ( Table 3) . Six patients are alive and well, three died from infections (3, 3 and 8 months after HSCT) and two of relapse (3 months and 3 years after HSCT). No Bone Marrow Transplantation patient with a significant decrease in LVEF has shown any evidence of congestive heart failure 2.5 to 10 years after transplantation.
Patients with low LVEF before transplantation
Eleven patients had an LVEF of less than 50% before transplantation. Of these, six had an improvement in the ejection fraction to more than 50%, three had a change of less than 5 in percentage points and two decreased 5 percentage points or more after HSCT. In one of these last two patients the LVEF decreased to 39% and he died 8 months after transplantation of ALL relapse but without signs of heart failure. In the other patient, the LVEF decreased to 35% but was 65% at follow-up 3 months later. None of the patients with less than 50% in LVEF before HSCT has shown any signs of heart failure after a follow-up time of 5 to 10 years.
Patients with a previous history of anthracycline treatment
LVEF values in patient groups based on the cumulative dose of anthracyclines received before transplantation are presented in Table 4 . The mean LVEF before transplantation in patients with no previous anthracycline treatment was 62.1% (range 44-81%) and in patients who had received anthracyclines 58.5% (38-63%) (P = 0.007). Also, when comparing group 0 (no anthracyclines) with patients in group 1 (Ͻ250 mg/m 2 ) the difference was significant (P = 0.04). The P value comparing LVEF in patients who had received less than 500 mg/m 2 (group 1 and 2) with patients who had received doses above 500 mg/m 2 (group 3) was 0.07 (58,8% vs 53.8%). The changes between pre-and posttransplant values were not significant in any of the groups. Significant decreases in LVEF in individual patients according to our definition were found in seven patients in group 0, three in group 1, one in group 2 and none in group 3. Table 5 shows the LVEF values in patients with CML, AML and ALL who received cyclophosphamide and TBI vs CY and busulfan as conditioning therapy. The pretransplant LVEF values were significantly higher in patients conditioned with TBI than in those receiving busulfan (61.5% vs 56.8%) (P = 0.01) but there was no significant change between pre-and post-transplant values in any of the two groups. A total of seven patients had a significant decrease in the LVEF after HSCT according to our definition. All these patients belonged to the TBI group but the difference in incidence between the groups was not significant (P = 0.35).
Comparison between conditioning therapy containing either TBI or busulfan
Discussion
Patients undergoing HSCT are exposed to several cardiotoxins including high-dose cyclophosphamide, radiation and infections. The aim of this study was to evaluate the effects of the transplantation procedure on cardiac function, in patients surviving transplantation. Previous studies have mainly focused on acute cardiotoxic effects but there are great differences in the reported incidence of cardiotoxicity in these studies. Kupari et al 29 found severe arrhythmias and heart failure in 5-10% of the patients, which is similar to Hertenstein et al 2 who found an overall cardiac toxicity of 4.5% and a life-threatening toxicity of 1.8%. 29 This contrasts to the results of Cazin et al 1 where acute cardiotoxic effects were found in 45% and the mortality was estimated to 9%. Possible reasons for the discrepancy are the higher doses of cyclophosphamide and more frequent cardiac examination in the later study. Kupari et al also performed echocardiographic examinations 1 month and 1 year after HSCT. An increase in mass index and pre-ejection period/ejection time and decrease in fractional shortening and peak normalized diameter lengthening rate was found after 1 month, but at follow-up 1 year after transplantation the measurements were no longer significantly different from the pretransplant values. 3 Carlsson et al 30 followed 111 patients with RVG examinations up to 5 years after autologous HSCT and found a significant decrease in LVEF in lymphoma patients 6 and 36 month after HSCT. In nonlymphoma patients there were no changes in cardiac function after transplantation. They found no increase in cardiac complications in patients with a low pre-transplant LVEF (Ͻ50%).
We performed radioventriculography before and after transplantation in 148 patients undergoing allogeneic or autologous HSCT. The accuracy of the RVG method for determining LVEF has previously been evaluated and these studies indicate excellent correlations compared to other methods such as contrast angiography. [31] [32] [33] [34] [35] Wackers et al 34 found a 1.4% (Ϯ1.2) and 1.6% (Ϯ1.4) variability for intraand interobserver RVG measurements, respectively. In the same study, variations between examinations performed on the same day and on separate days were 3.3% (Ϯ3.1%) and 4.3 (Ϯ3.1%), respectively. Generally, variations were more pronounced in patients with normal LVEF levels compared to patients with decreased LVEF and the investigators concluded that nonrandom physiologic alterations should be attributed to changes of more than 10% in patients with normal heart function and more than 5% in patients with abnormal heart function. Marshall et al 33 performed repeated RVG examinations in the same patient with an average interval of 4 days showing similar variation rates.
Significant decrease in LVEF was defined as a decrease of more than 10% points or a decrease to less than 50%. The cut-off values should be interpreted carefully as such limits are always arbitrary. However, the definitions in this study were based on previous studies which have used RVG for prediction of clinical heart failure. As mentioned above, the normal variability with this method can be estimated to 10 and 5 percentage points in patients with normal and abnormal heart function, respectively. 34 Alexander et al 27 evaluated the cardiotoxic effects of anthracyclines by the RVG method and defined mild cardiotoxicity as a decline of more than 10 percentage points. They concluded that this limit could be used as an early warning of anthracycline cardiotoxicity. A decrease of more than 15 percentage points to a LVEF value of less than 45% in the same study predicted severe heart failure in patients who received further treatment and these cut-off values seemed not to be sufficiently sensitive. In 1987, Schwart et al recommended guidelines for the monitoring of patients treated with anthracylines based on decreases of more than 10 percentage points and with a normal LVEF defined by a 50% limit. 27, 28 Effect on systolic function was evaluated in the whole patient group and in the subgroups according to diagnosis and graft type. The impact of TBI compared to that of bus-ulfan in the conditioning regimen and the role of previous treatment with anthracyclines were also studied.
The baseline LVEF significantly differed between patients with CML and those with acute leukemia or multiple myeloma. This difference may be explained by the fact that only five of the CML patients had a history of previous anthracycline treatment whereas it was considerably more common in patients with the other diagnoses. However, comparing CML with breast cancer the difference was not significant even though all breast cancer patients had received anthracyclines. This lack of significance could also be due to the small number of breast cancer patients. The difference found between chronic and acute leukemia corresponds to the results from Kupari et al 3 who showed that CML patients had longer peak normalized diameter lengthening rates than did patients with acute leukemia before HSCT.
No significant changes in mean ejection fraction were seen comparing pre-and post-transplant examinations. This was true for all diagnostic subgroups and with autologous as well as allogeneic recipients. On the contrary, a slight but insignificant increase in mean LVEF was seen in some groups. Only 8% of our patients had a significant decrease in ejection fraction. The majority of these patients had a decrease of more than 10 percentage points and only two patients decreased to below 50%.
The comparison between autologous and allogeneic recipients is especially important. Theoretically, more pronounced cardiotoxic effects could be expected in allogeneic recipients as a result of a different spectrum of infectious complications, and possibly also as an effect of GVHD. This comparison was made by Hertenstein et al 2 who, despite this expectation found a higher incidence of heart failure in autologous recipients. However, it is difficult to draw any conclusion from their study as the number of autologous recipients was small. In our study no significant change was seen in LVEF values, either in autologous or allogeneic transplants. The number of patients with a significant decrease was more common in allogeneic recipients but the difference was not significant and more important, none of these patients have developed signs of heart failure. Another group that we studied separately involved patients with less than 50% LVEF before HSCT as they could be considered to be more vulnerable to the impact of cardiotoxic factors. In these 11 patients, six increased their LVEF to Ͼ50% at the second examination and none have shown signs of heart failure.
Patients with leukemias were conditioned with cyclophosphamide in combination with either TBI or busulfan. Busulfan has been reported to induce cardiac fibrosis but exposure to radiation is generally considered to be more cardiotoxic. However, we found no indication that TBI had a greater impact on LVEF than did busulfan.
Patients previously treated with anthracyclines were divided into three groups according to the cumulative dose given before transplantation. Patients not previously exposed to anthracyclines had significantly higher ejection fractions before HSCT compared to patients previously treated. This difference was also found when comparing the group with the lowest cumulative dose (Ͻ250 mg/m 2 ). Patients who had received anthracyclines up to 500 mg/m 2 Bone Marrow Transplantation had higher pre-transplant LVEF values than did patients with a cumulative dose exceeding 500 mg/m 2 but this difference was not significant (P = 0.07). The lack of significance is probably due to the fact that only five patients belonged to the latter group. The tendency towards impaired ejection fraction in the high-dose group corresponds to the view that 500 mg/m 2 doxorubicin is an approximate threshold for impact on heart function. LVEF remained unchanged in all groups after BMT indicating that previous treatment with anthracyclines does not constitute a risk for decline in cardiac function after HSCT at the time of our follow-up.
In conclusion, it seems that the cardiotoxic factors of the HSCT procedure are insufficient to exert an effect on cardiac systolic function in most patients, measured as a change in ejection fraction 1-7 months after the transplantation. Patients with a low LVEF before HSCT and patients with a significant decline in LVEF after HSCT were not at greater risk of developing clinical signs of heart failure. Despite the fact that treatment with anthracyclines prior to transplantation resulted in decreased cardiac function, these patients were not at higher risk of developing heart failure after transplantation, and neither did the use of TBI vs busulfan as conditioning appear to affect cardiac function after HSCT. However, even though we found no significant impairment of cardiac function during our observation period, we cannot rule out the possibility that the transplantation procedure could induce damage to the myocardium which may only become clinically evident after many years.
